Systemic Therapy in Patients with LA-SCCHN: Future Directions

CAN-eng

$0

gratuit

MOC - Section 1

20 minutes

Oncologie

0,75 crédits

Description du cours

Head and neck cancer is the sixth most common cancer in Canada. The majority of head and neck cancers (∼90 %) are squamous cell carcinomas, and most patients (∼60 %) are diagnosed with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). Surgery is preferable in oral cavity cancer and T4 cases of larynx cancer. Surgery for oropharyngeal cancer is an option when the neck is clinically negative in order to avoid radiotherapy. Human papillomavirus (HPV)-driven oropharyngeal cancers represent distinct entities compared to HPV-unrelated oropharyngeal cancers. Chemoradiation as an organ preservation approach is often selected as the treatment of choice in oropharyngeal cancer. Ongoing research and clinical trials continue to refine our understanding of LA-SCCHN and pharmacotherapeutic treatment options, offering the potential to change practice and improve patient outcomes.


Ce programme a reçu une subvention éducative sans restriction ou un soutien en nature de l'EMD Serono.

Détails du cours

Date d'expiration : 2025-05-21

Métiers: Spécialiste

Faculté

Anna Spreafico, M.D., Ph.D.

Denis Soulières, M.D., M.Sc., FRCPC

Accréditation

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University Office of CPD. You may claim a maximum of 0.75 hours (credits are automatically calculated).

Session ID: 00016585

Objectif(s) d'apprentissage

After viewing this expert brief, participants will be better able to:

  • Reconnaître la nécessité de nouvelles approches thérapeutiques pour le LA-SCCHN
  • Résumer les principales conclusions des récents essais majeurs du LA-SCCHN
  • Identifier essais de phase 3 pour LA-SCCHN avec des résultats attendus dans les deux prochaines années